NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY
WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS
VANCOUVER, British Columbia, Oct. 25, 2017 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc.
(the “Company” or “RavenQuest”) – (CSE:RQB) is pleased to announce that further to the Company’s news releases September 29, 2017
announcing the acquisition (the “AGB Acquisition”) of 99.23% of the outstanding common shares of Alberta Green
Biotech Inc. (“AGB”), and the Company’s news release dated October 23, 2017, the Company is pleased to announce it
has completed the acquisition of a further 400,000 common shares of Alberta Green Biotech Inc. (“AGB”) in exchange
for the issuance of 57,206 common shares of the Company on the basis of 0.143015519 common shares of the Company for every one (1)
common share of AGB. Following completion of this acquisition, the Company now holds approximately 99.9% of the issued and
outstanding common shares of AGB.
The AGB Acquisition, together with the acquisition of the business and assets of the CL2G group of companies
(the “CL2G Group”) announced September 28, 2017, are further described in the Company’s Canadian Securities
Exchange (the “Exchange”) Form 2A Listing Statement dated September 28, 2017 (the “Listing Statement”) filed under
the Company’s profile on the Exchange’s website.
Stock Options
In addition, the Company announces that today it is granting stock options to directors, officers, employees and
consultants of up to 4,000,000 common shares at an exercise price of $1.25 for five years, all option grants will be subject to the
Company’s vesting policies.
About RavenQuest Biomed Inc.
RavenQuest Biomed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis
production, management services & consulting and specialized research & development.
For further details on the Company readers are referred to the Company's web site (www.rqbglobal.com) and its Canadian regulatory filings on SEDAR at www.sedar.com.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
"George Robinson"
Chief Executive Officer
For further information, please contact:
Mathieu McDonald, Corporate Communications
1-877-282-1586
Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been
prepared by management.
Cautionary Note Regarding Forward-Looking Statements
All statements in this press release, other than statements of historical fact, are "forward-looking
information" with respect to the Company within the meaning of applicable securities laws, including statements with respect
to the Fundamental Change and the transactions contemplated in connection therewith. The Company provides forward-looking
statements for the purpose of conveying information about current expectations and plans relating to the future and readers are
cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent
risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts,
predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives,
strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified
and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could
cause actual actions, events or results to differ materially from those described in forward-looking information, there may be
other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that
such information will prove to be accurate as actual results and future events could differ materially from those anticipated in
such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as
a result of new information, future events or otherwise unless required by law.
UNITED STATES ADVISORY. The securities referred to herein have not been and will not be registered
under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), have been offered and sold outside the
United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered,
sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in
Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an
exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities
must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States
in which such offer, solicitation or sale would be unlawful.
